Day One Biopharmaceuticals’ (DAWN) “Buy” Rating Reiterated at Needham & Company LLC
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $33.00 price objective on the stock. Needham & Company LLC’s price target indicates a potential upside of […]
More Stories
Future plc (LON:FUTR) Announces Dividend of GBX 3.40
Future plc (LON:FUTR – Get Free Report) announced a dividend on Friday, December 5th,Upcoming Dividends.Co.Uk reports. Investors of record on...
XAI Octagon Floating Rate & Alternative Income Trust (XFLT) to Issue Monthly Dividend of $0.08 on February 3rd
XAI Octagon Floating Rate & Alternative Income Trust (NYSE:XFLT – Get Free Report) announced a monthly dividend on Thursday, January...
AbbVie Inc. (NYSE:ABBV) Shares Acquired by Eastern Bank
Eastern Bank grew its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 36.7% in the 4th quarter, according to...
Miracle Mile Advisors LLC Increases Stock Holdings in Alphabet Inc. (NASDAQ:GOOG)
Miracle Mile Advisors LLC grew its holdings in Alphabet Inc. (NASDAQ:GOOG – Free Report) by 48.1% in the 4th quarter,...
Eastern Bank Purchases 6,070 Shares of Visa Inc. (NYSE:V)
Eastern Bank boosted its stake in shares of Visa Inc. (NYSE:V – Free Report) by 1.9% during the fourth quarter,...
Asia Dragon (DGN) To Go Ex-Dividend on January 16th
Asia Dragon (LON:DGN – Get Free Report) announced a dividend on Thursday, January 9th,Upcoming Dividends.Co.Uk reports. Stockholders of record on...